Acute myocardial infarction

Prognostic effect of discontinuing renin–angiotensin–aldosterone-system-inhibitor (RAASi) for patients with heart failure (HF) after acute myocardial ...

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Kardiologia Polska (Polish Heart J.) 74, 1037–1147 (2016). The Lancet 393, 61–73 (2019). [1](/articles/s41598-023-30700-1#MOESM1) and [2](/articles/s41598-023-30700-1#MOESM1)). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. [25](#ref-CR25), [26](#ref-CR26), [27](#ref-CR27), [28](#ref-CR28), [29](/articles/s41598-023-30700-1#ref-CR29). [3](/articles/s41598-023-30700-1#Fig3)). The need for continuation of HF medications after recovery of LVEF can sometimes be questioned due to adverse drug reactions, financial burden, polypharmacy, and uncertain benefit of indefinite HF medications in patients with HFresEF [25](/articles/s41598-023-30700-1#ref-CR25). [18](/articles/s41598-023-30700-1#ref-CR18). [17](/articles/s41598-023-30700-1#ref-CR17). [12](/articles/s41598-023-30700-1#ref-CR12). GDMT for HFrEF can improve myocardial function in up to half of patients [5](#ref-CR5), [6](#ref-CR6), [7](/articles/s41598-023-30700-1#ref-CR7), and patients with restored myocardial function (heart failure with restored ejection fraction [HFresEF]) tend to have better clinical outcomes [8](#ref-CR8), [9](#ref-CR9), [10](#ref-CR10), [11](/articles/s41598-023-30700-1#ref-CR11).